MedPath

Ranitidine

Generic Name
Ranitidine
Brand Names
Good Sense Acid Reducer, Wal-zan, Zantac
Drug Type
Small Molecule
Chemical Formula
C13H22N4O3S
CAS Number
66357-35-5
Unique Ingredient Identifier
884KT10YB7
Background

Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as cimetidine and famotidine. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion. Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.

The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.

Indication

This drug is used alone or with concomitant antacids for the following conditions: short-term treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid levels. It also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose. In addition to the above, ranitidine can be used for the treatment of GERD symptoms, treatment of erosive esophagitis (endoscopically diagnosed) and the maintenance of gastric or duodenal ulcer healing.

Associated Conditions
Acid Aspiration Syndrome, Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastric hypersecretion, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Osteoarthritis (OA), Peptic Ulcer Disease, Rheumatoid Arthritis, Stress Ulcers, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Benign gastric ulcer healing, Benign gastric ulcers, Duodenal ulcer healing, Post-operative peptic ulcer, Recurrent hemorrhage from bleeding ulcers

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Phase 2
Terminated
Conditions
T-lymphoblastic Lymphoma/Leukaemia
T-cell Type Acute Leukemia-Precursor
Interventions
First Posted Date
2016-12-21
Last Posted Date
2022-03-21
Lead Sponsor
Sanofi
Target Recruit Count
14
Registration Number
NCT02999633
Locations
🇺🇸

Investigational Site Number 8400001, Houston, Texas, United States

🇺🇸

Investigational Site Number 8400002, Atlanta, Georgia, United States

🇫🇮

Investigational Site Number 2460001, Helsinki, Finland

and more 14 locations

: Vascular Function in Health and Disease

Phase 1
Recruiting
Conditions
Chronic Obstructive Pulmonary Disease
Pulmonary Artery Hypertension
Heart Failure
Hypertension
Interventions
Other: Maximum Exercise Tests
Drug: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
Other: Angiotensin-II, Valsartan
Drug: Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine
Drug: BQ-123, MitoQ, BH4
First Posted Date
2016-11-17
Last Posted Date
2024-11-21
Lead Sponsor
Russell Richardson
Target Recruit Count
420
Registration Number
NCT02966665
Locations
🇺🇸

George E Wahlen VA Medical Center, Salt Lake City, Utah, United States

Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia

First Posted Date
2016-11-02
Last Posted Date
2016-11-04
Lead Sponsor
Federal University of São Paulo
Target Recruit Count
40
Registration Number
NCT02953210
Locations
🇧🇷

Faculdade de Ciências Médicas da Santa Casa de São Paulo, Sao Paulo, Brazil

Does Pantoprazole Reduce the Anti-platelet Effect of Clopidogrel?

Not Applicable
Completed
Conditions
Antiplatelet Effect
Interventions
First Posted Date
2016-04-11
Last Posted Date
2016-04-11
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
42
Registration Number
NCT02733640
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

Not Applicable
Withdrawn
Conditions
Acid Reflux
Stridor
Laryngomalacia
Interventions
First Posted Date
2016-03-07
Last Posted Date
2017-11-17
Lead Sponsor
Stanford University
Registration Number
NCT02700087
Locations
🇺🇸

Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

First Posted Date
2015-09-22
Last Posted Date
2015-09-22
Lead Sponsor
Canadian Network for Observational Drug Effect Studies, CNODES
Target Recruit Count
4238504
Registration Number
NCT02555852
Locations
🇨🇦

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada

Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

First Posted Date
2015-05-12
Last Posted Date
2017-01-24
Lead Sponsor
Sanofi
Target Recruit Count
21
Registration Number
NCT02441894
Locations
🇯🇵

Investigational Site Number 392008, Kita-gun, Japan

🇯🇵

Investigational Site Number 392001, Shinjuku-ku, Tokyo, Japan

🇯🇵

Investigational Site Number 392004, Chuo-ku, Chiba, Japan

and more 5 locations

Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering

First Posted Date
2015-05-12
Last Posted Date
2018-07-17
Lead Sponsor
Lagos State Health Service Commission
Target Recruit Count
130
Registration Number
NCT02441673

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

First Posted Date
2014-07-31
Last Posted Date
2016-06-09
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
58
Registration Number
NCT02205489
Locations
🇧🇪

Investigational Site Number 056001, Brussels, Belgium

🇳🇱

Investigational Site Number 528001, Breda, Netherlands

🇳🇱

Investigational Site Number 528002, Rotterdam, Netherlands

and more 17 locations

A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain

Phase 4
Completed
Conditions
Dyspepsia
Interventions
First Posted Date
2014-07-22
Last Posted Date
2014-07-22
Lead Sponsor
Pamukkale University
Target Recruit Count
286
Registration Number
NCT02197143
Locations
🇹🇷

Pamukkale Universty, Denizli, Turkey

© Copyright 2025. All Rights Reserved by MedPath